Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-03-16 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding amendments to the company's Articles of Association (公司章程). It includes extensive legal and regulatory references, detailed provisions about shareholder rights, capital increase methods, share repurchase rules, board and shareholder meeting powers, and transaction approval thresholds. The content is focused on governance structure, shareholder obligations, and corporate rules rather than financial results or operational performance. There is no indication of financial statements, audit opinions, earnings data, or investor presentations. The document is not a brief announcement but a substantive governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-03-16 Chinese
长春百克生物科技股份公司2021年年度报告
Annual Report Classification · 100% confidence The document is titled '2021 年年度报告' which translates to '2021 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, financial statements, audit report references, and comprehensive disclosures typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes sections such as management discussion and analysis, financial data, audit opinions, and corporate governance, all consistent with an official annual report filing. Therefore, the document is classified as an Annual Report (10-K equivalent). FY 2021
2022-03-16 Chinese
长春百克生物科技股份公司第五届董事会第四次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the fifth board of directors of Changchun Baker Biological Technology Co., Ltd. It includes approvals of various reports such as the 2021 Board Work Report, 2021 Financial Settlement Report, 2022 Financial Budget Report, 2021 Profit Distribution Plan, and the 2021 Annual Report full text and summary. It also mentions that these reports and proposals will be submitted to the shareholders' meeting for approval. The document is primarily about board meeting decisions and approvals, not the reports themselves. It also references other announcements published on the stock exchange website for detailed reports. The document length is 2513 characters, which is relatively short and mainly serves as a meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management decisions rather than the full reports or financial statements themselves.
2022-03-16 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司2021年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the special audit opinion on the storage and use of raised funds by Changchun Baike Biotechnology Co., Ltd. for the year 2021. It includes specific financial figures about the amount raised, usage, balances, and compliance with regulatory requirements. The document references regulatory guidelines related to fundraising and fund management, and it contains detailed tables and explanations about the use of funds, investment projects, and compliance. This is not a general annual report or earnings release but a specialized audit or verification report focused on fundraising and fund usage. It is not a mere announcement or certification but contains substantive financial and compliance data. Therefore, it fits the category of an Audit Report / Information (AR). FY 2021
2022-03-16 Chinese
长春百克生物科技股份公司2021年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the deposit and actual use of raised funds for the year 2021 by Changchun Baike Biotechnology Co., Ltd. It details the amount of funds raised through an IPO, the usage of these funds, the balance remaining, and compliance with regulatory requirements regarding the management of raised funds. It includes detailed tables on the use of funds, bank account balances, and auditor and sponsor opinions on the proper use of the funds. The document is a specialized report focusing on the management and use of capital raised by the company, which aligns with the definition of a Capital/Financing Update (CAP) filing. It is not a general annual report or earnings release, nor is it a regulatory announcement or proxy material. The length and detail confirm it is a substantive report, not just an announcement of a report. Therefore, the appropriate classification is CAP.
2022-03-16 Chinese
长春百克生物科技股份公司2021年年度股东大会通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2021 Annual General Meeting (AGM) of Changchun Baike Biotechnology Co., Ltd., including details on the meeting date, voting methods, agenda items, and proxy voting instructions. It does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is 3112 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2022-03-16 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.